IκB kinase subunit alpha (IKKalpha), a key component of the NFκB pathway, is implicated in
prostate cancer progression and bone remodelling, but its role in the regulation of prostate …

Bu araştırmada 01/01/2000-31/12/2018 tarihleri arasında Bursa Uludağ Üniversitesi Sağlık
Uygulama ve Araştırma Merkezi'nde metastatik kastrasyon rezistan prostat kanseri tanısı …

The present invention concerns methods for treating a proliferation disorder, such as
prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of …

In Western populations, prostate cancer is one of the leading causes of cancer-related
deaths in males, second only to lung cancer [1]. In 2015, the Australian Bureau of Statistics …

Prostate cancer metastasis to the bone is a frightening cause of death world-wide. Patients
do not live a functional and active life before they eventually die. The major reason for …

The present invention concerns methods for treating a proliferation disorder, such as
prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of …

The skeleton is the most common site of prostate cancer bone metastasis, and at present,
there are no curable treatments for these patients. To further understand what stimulates …

Prostate cancer (PCa) is the second most common cancer affecting men in Canada and
USA, and accounts for thousands of deaths each year. While most prostate tumours are …

Prostate cancer (PCa) is the second leading cause of cancer-related deaths among men.
Evidence suggests that age and obesity, conditions associated with adipocyte accumulation …

Breast, lung, and prostate cancers are the three most common malignancies to metastasize
to the temporal bone. Still, metastatic prostate cancer of the temporal bone is a rare finding …